Practice Description:
David R. Lallouz is a senior associate in the firm’s Corporate, Capital Formation and Securities Law group. David has extensive experience in corporate transactions, both public and private, including mergers and acquisitions, private equity and general corporate matters.
David regularly advises clients in structuring, negotiating and implementing a broad range of corporate and commercial transactions, and has represented clients in numerous stock and asset acquisitions and dispositions, financings, venture capital transactions, and significant public offerings on the New York Stock Exchange. His practice has included clients ranging from closely-held startups to international investment banks hedge funds. David also represents investors in PIPE (private investment in public equity) transactions and registered direct offerings.
In addition to practicing in New York, David began his career in the Canadian province of Quebec, where he remains admitted to practice. Prior to joining Tannenbaum Helpern, David was a partner in a leading international law firm based in Montreal, where his experience included Canadian, U.S. and cross-border transactions.
Additionally, David regularly provides counsel to clients relating to general corporate matters, entity formation and capitalization, as well as their commercial and contractual relationships.
David is fluently bilingual in English and French and advises clients in both languages.
David has been selected for inclusion as a “Rising Star” in New York Super Lawyers 2011.
Significant Matters:
Sale of a significant investment manager with approximately $11 billion of assets under management to a leading Japanese investment bank.
2011 public offering of over $660 million, and 2009 public offering of approximately $500 million for a significant commodity exchange traded fund (ETF) listed on the NYSE-ARCA.
Sale of a classic and contemporary world cinema film distributor and home entertainment company.
Numerous private investments in public equity and registered direct offerings.
Cross-border acquisitions and dispositions involving manufacturing, health-care, IT and emerging-technology businesses.
Various private placements and venture capital financings in the biotech and telecommunications industries.
Numerous private acquisitions involving U.S. investment banks, including the acquisition of a NYSE market-maker.
Senior and subordinated acquisition financings on behalf of both buyers and banks.